Services for population genomics initiatives
Your European partner for your population genomics study
Leverage a seamlessly scalable infrastructure across technology platforms.
Your Challenge
We help you set up population genomics databases in order to:
Understand the epidemiolocial landscape for a disease
Identifying the genetic defects and variants that are linked to a condition, their influence on disease onset and progression, and their relationship to phenotype.
Drive the discovery and development of new medicines at all stages
By helping to identify druggable targets in disease pathways, guide the development of medicines to edit/replace specific genes (gene therapies).
Identify defective genes and genetic variants
Allow the personalization of treatment with medicines via pharmacogenomics
Where genetic variants that have an impact on patient response to drugs.
Genotyping by Microarrays
Population scale screening arrays combine universal genome-widecontent, curated clinical research variants and QC markers
NGS-based Genotyping: Mid-Plex
The midplex genotyping approach is highly accurate, robust, cost-efficient, flexible and customisable
Low Pass Sequencing
Next Generation Genotyping: Discover biomarkers with cost-efficient “Low Pass Whole Genome Sequencing”
Microarrays
Genotyping by Microarrays
Population scale screening arrays combine universal genome-wide content, curated clinical research variants and QC markers.
Genome-wide multiethnic GWAS backbone
- Build on whole-genome reference data from 1000 genomes
- Global content is cross-population and population specific
Laboratory information management system
- Disease and trait associated markers (ClinVar / PharmGKB / NHGR-EBI)
- Cross-population and population specific exonic content
- HLA alleles and extended MHC region.
Quality control markers
- Sample identification / tracking, ancestry determination, stratification
NGS
Next Generation Sequencing
The midplex genotyping approach is highly accurate, robust, cost-efficient, flexible and customisable.
SNP biomarker validation
- Population screening
- Biobank screening (retrospective analysis of germline SNPs)
- Disease screening.
Accuracy and robustness
- On average > 97% successful SNP design and > 98% sample call rate
- Low DNA amounts needed (20 ng): Crude DNA extraction possible for blood, tissue and cells
- High multiplexing capabilities at low costs and fast TAT (1 – 3 weeks).
Flexibility and customisation
- Completely customized sets of SNPs (10 – 1,000)
- Additional samples can be added any time
- Flexible system allowing implementation of additional SNPs at a later stage
- Analysis of either one SNP or several SNPs per target region
Low Pass Sequencing
Next Generation Genotyping by Low Pass Sequencing
Discover biomarkers with cost-efficient “Low Pass Whole Genome Sequencing”.
Low pass whole genome sequencing
- < 10x coverage
- 150 paired-end sequencing on NovaSeq 6000
Cost-efficient alternative to WGS
- Detection of noven SNPs
- Missing genomic region can be filled by “imputation”
Ideal for large scale projects
- Population screening of a > 15.000 patient cohort from a biobank
Most relevant applications
- Genome-wide association studies (GWAS)
- Population screening
- Ancestry analysis
- Biobank profiling
- Investigation of complex diseases
Technology Overview
Designed to meet the unique demands of your project
Explore all available options.
GENOMICS
Overview
Genomics is pivotal in population health research, offering insights into disease genetics and aiding personalized medicine. Techniques like genotyping identify genetic markers for health conditions, while next-generation sequencing uncovers broader genetic variations. These tools are essential in epidemiological studies, helping to track disease trends and inform public health strategies, ultimately advancing our understanding of the genetic basis of diseases and their impact on populations.
Platforms
- Oxford Nanopore (Long-Read)
- Illumina
- Thermo Fisher
- MGI
Workflows
- Whole Genome Sequencing
- Sequencing only
- Whole exome sequencing
- Shotgun metagenomics
EPIGENOMICS
Overview
Epigenomics, exploring beyond genetic sequences to how genes are expressed, is crucial in population health studies. It helps in understanding how environmental factors and lifestyle choices influence gene expression, contributing to disease development. This field is key in unraveling the complex interplay between genetics and the environment, providing a more comprehensive picture of health and disease mechanisms, highlighting how external factors can shape genetic outcomes.
Platforms
- Oxford Nanopore (Long-Read)
- Illumina
- MGI
Workflows
- Long read on Oxford Nanopore
- Bisulphite sequencing
- Enzymatic conversion
- Illumina EPIC & MSA arrays
TRANSCRIPTOMICS
Overview
Transcriptomics is a vital component in population health research, focusing on the study of RNA transcripts to understand gene expression patterns. This field has become even more relevant with the identification of over 190 RNA modifications, which add another layer of complexity to gene expression regulation. By analyzing these RNA molecules, transcriptomics provides critical insights into how genes are activated or silenced in different health conditions, offering a deeper understanding of disease mechanisms and potential therapeutic targets.
Platforms
- Oxford Nanopore (Long-Read)
- Illumina
- Thermo Fisher
- MGI
Workflows
- RNA seq
PROTEOMICS
Overview
Proteomics, the study of proteins, is fundamental in population health research. It delves into protein structures, functions, and interactions, providing crucial insights into various biological processes and disease mechanisms. Understanding protein dynamics helps in identifying biomarkers for diseases and potential therapeutic targets, enhancing disease diagnosis and treatment strategies. Proteomics is key in understanding the functional implications of genetic information, bridging the gap between genotype and phenotype in population health studies.
Platforms
- Olink
- Somalogic
- Illumina
Workflows
- Olink Explore HT
- Olink targetted panels
- SomaScan panels
Free consulting for your population genomics project
Speak to our population genomics experts about your ideas
Our team of experts can advise and assist you with all
the information on our end-to-end service offer.
References
Project Examples
Our Future Health, UK
Eurofins Genomics partners in pioneering UK health project, providing advanced genotyping for 5 million participants. Advancing precision medicine and personalised healthcare with an unwavering commitment to genomic advancements. Upholding the highest standards for quality, accuracy, and efficiency in genotyping services. Working with partners to revolutionise healthcare through genomics.
Work conducted by Eurofins Genomics:
- Genotyping will be performed on illumina custom array with 700k SNPs
- We are building a dedicated lab in UK
- The goal of the Our Future Health program is to facilitate the discovery and development of new methods of prevention, early detection and treatment of a wide range of diseases
- Today, 59% of UK citizens aged 65 years or older have two or more serious health conditions, and this statistic has been projected to reach 70% by 2035. With the recruitment of five million adult volunteers, this research program has the potential to improve the long-term health of millions of people in the UK and globally. The insights gained into links between DNA and diseases through this program will accelerate the development of innovative solutions to help people to live healthier lives for longer.
The Simpler Project, Uppsala University
The infrastructure SIMPLER consists of questionnaire data and biological samples for research on how dietary, lifestyle factors and genetics affect health, especially during the latter part of life.
Work conducted by Eurofins Genomics:
- DNA extraction of 38.000 saliva and blood samples
- Genotyping on microarrays of 40.500 samples
- The success rate (sample to genotype) has been extremely high, above 99%
- The project began in late spring 2019 and was completed on time as scheduled at the end of 2020
- Genotyping was performed on the Illumina Infinium Global Screening Array (GSA MD 3.0)
“We are very happy with Eurofins’ competence and professional approach” comments Anna-Karin Kolseth, project coordinator, SIMPLER.
Low-Pass Sequencing for "Top-20 Pharmaceutical Company"
Fast, cost-efficient and high throughput Next Generation Sequencing for Top 20 pharma client.
Sucessfully completed a few weeks time 18.000 sample cohort up to 2.500 WGS samples per week.
Work conducted by Eurofins Genomics:
- Dedicated, pro-active Consulting & Project Management
- Incl. Weekly update calls
- Tailored Quality Control reports
- Customized Data Transfers
Free consulting for your population genomics project
Speak to our population genomics experts about your ideas
Our team of experts can advise and assist you with all
the information on our end-to-end service offer.
Approved by your peers from Ancestry, Genealogy, Health & Wellness
We are a trusted population genomics brand around the globe
We cooperate with renowned organisations, ranging from small to large-scale enterprises to provide ‘best-in-class’ genomic services to both established and new, emerging consumer genomics markets. Scientists around the world recognise and trust the Eurofins brand for its reputation for quality, timeliness and efficiency. We host only industry-leading platforms for DNA extraction, genotyping, sequencing and related consumer genomics applications.
Quality you can rely on
Work with a fully certified population genomics partner
ISO 17025
Guaranteed confidentiality and integrity of testing data.
Testing results are recognised by authorities and customs, etc. for the release of pharmaceuticals and food and feed, in the case of legal implications.
ISO 13485
Full documentation and traceability of production processes.
Compliance with regulatory requirements in regard to EU, US and other national directives about medical devices, in vitro Diagnostics or medicinal products.
Quality management system is in line with the FDA QSR standards.
GDPR
All data is stored and processed on German servers.
We do not share data with third parties.
Only necessary data is requested.
Customer data is stored using the most advanced security tools.
Customer voice
„We are very happy to work with Eurofins Genomics because it has allowed us to absorb our exponential growth in the number of samples analysed, while maintaining exceptional process quality.“
Customer voice
„Not only do they have one of the most advanced laboratories in Europe, but also the human team behind them is amazing. We look forward to continuing to grow with them.“
Your dedicated Consumer genomics Expert
Daniel Langhoff
Business Development Director
Eurofins Genomics Europe